



RUBRA
MEDICAMENTS LTD.

Reg. Office: 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

Email ID: rubraltd@gmail.com | Website: www.rubramed.com

CIN: L74110MH1991PLC326598 | Tel: +91 9167469649

May 25, 2022

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code : 531099
Sub : Outcome of Board Meeting

Dear Sir / Madam,

This is to inform you that the Board of Directors of the Company at its meeting held on Wednesday, May 25, 2022, inter alia, has considered and approved the following:

- A. Audited Standalone Financial Results for the year ended March 31, 2022
- B. Asset liability statement,
- C. Cash Flow Statement,
- D. Audit Report thereon.
- E. Declaration for unqualified report

You are requested to kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Rubra Medicaments Limited**



Abha Kapoor
Director (Finance) and CFO
DIN – 02799429



DD & COMPANY

CHARTERED ACCOUNTANTS

Auditor's Report On Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Rubra Medicaments Limited

We have audited the financial results of **Rubra Medicaments Limited** for the quarter ended March 31, 2022 as well as the year to date results for the year ended March 31, 2022 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial result have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date financial result:

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

(ii) give a true and fair view of the net profit/loss and other financial information for the quarter ended March 31, 2022 as well as the year to date results for the year ended March 31, 2022.

Place: Mumbai
Date: May 25, 2022

For M/s DD & Company
Chartered Accountants
Firm Registration No: FRN 129273W



Membership No: 045393
UDIN: 22045393AJNYSU6283

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981
TEL NO: 62215449; 66712284 Email: itpaglobal@gmail.com

RUBRA MEDICAMENTS LIMITED

Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2022

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Figures for current period ended	Figures for previous period ended
		31-Mar-22	31-Dec-21	31-Mar-21	31-Mar-22	31-Mar-21
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from Operations	62.00	43.50	29.75	201.11	48.50
II	Other Income	0.08	0.00	0.00	0.08	0.00
III	Total Income (I + II)	62.08	43.50	29.75	201.19	48.50
IV	Expenses:					
	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	0.00	1.92	8.26	51.99	8.26
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	12.21	2.07	16.45	22.57	19.54
	Finance Costs	0.00	0.00	0.03	0.01	0.04
	Depreciation & amortisation expense	0.04	0.04	0.04	0.16	0.16
	Other Expenses	50.90	43.55	4.27	128.69	19.68
	Total Expenses (IV)	63.15	47.58	29.05	203.42	47.68
V	Profit / (loss) before exceptional items and tax (III-IV)	-1.07	-4.08	0.70	-2.23	0.82
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00
VII	Profit / (loss) before tax (V-VI)	-1.07	-4.08	0.70	-2.23	0.82
VIII	Tax Expense:					
	(1) Current tax	0.62	0.00	0.25	1.42	0.25
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	-1.69	-4.08	0.45	-3.65	0.57
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	-1.69	-4.08	0.45	-3.65	0.57
XIV	Other comprehensive income					
	A (i) Items that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-1.69	-4.08	0.45	-3.65	0.57
XVI	Earnings per equity share (for continuing operation):					
	(1) Basic	0.00	0.00	0.00	0.00	0.01
	(2) Diluted	0.00	0.00	0.00	0.00	0.01
XVII	Earnings per equity share (for discontinued operation):					
	(1) Basic					0.01
	(2) Diluted	0.00	0.00	0.00	0.00	0.01
XVIII	Earnings per equity share (for discontinued & continuing operation):					
	(1) Basic	0.00	0.00	0.00	0.00	0.01
	(2) Diluted	0.00	0.00	0.00	0.00	0.01
	NOTES:					
1	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.					
2	The Segment - wise details are not applicable to the Company as the Company has only one segments.					
3	Previous period's figures have been reclassified / regrouped, wherever necessary.					

For Rubra Medicaments Limited



Abha Kapoor
Director (Finance) & CFO
DIN: 02799429

Place: Mumbai
Date:- May 25,2022

RUBRA MEDICAMENTS LIMITED

(Rs. in Lakhs)

STATEMENT OF ASSETS AND LIABILITIES

	Particulars	Figures as at the end of current reporting period	Figures as at the end of the previous reporting period
		31-Mar-22	31-Mar-21
		Audited	Audited
	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	1.20	1.36
	(b) Capital work-in-progress	-	-
	(c) Investment property	-	-
	(d) Goodwill	-	-
	(e) Other intangible assets	-	-
	(f) Intangible assets under development	-	-
	(g) Biological assets other than bearer plants	-	-
	(h) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Loans	-	-
	(iv) Others (to be specified) - Advances	-	-
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	-	-
	Total non-current assets	1.20	1.36
2	Current assets		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	66.63	22.05
	(iii) Cash and cash equivalents	0.13	0.86
	(iv) Bank balances other than (iii) above	1.49	50.77
	(v) Loans	11.50	11.50
	(vi) Others to be specified	-	-
	(c) Current tax assets (net)	-	-
	(d) Other current assets	3.74	3.93
	Total current assets	83.49	89.11
	Total assets	84.69	90.47
1	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	546.83	546.83
	(b) Other equity	-488.72	-485.06
	Total equity	58.11	61.77
	LIABILITIES		
2	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (net)	0.04	0.04
	(d) Other non-current liabilities	-	-
	Total non-current liabilities	0.04	0.04
	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	0.06	0.12
	(iii) Other financial liabilities (other than those specified in item (a))	-	-
	(b) Other current liabilities		
	(c) Provisions, current	26.48	28.54
	(d) Current tax liabilities (Net)	-	-
	Total current liabilities	26.54	28.66
	Total liabilities	26.58	28.70
	Total Equity and Liabilities	84.69	90.47

For Rubra Medicaments Limited

Place: Mumbai
Date:- May 25, 2022



Abha Kapoor
Director (Finance) & CFO
DIN: 02799429

RUBRA MEDICAMENTS LIMITED

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2022

	Particulars	March 31, 2022	March 31, 2021
		In Lakh	In Lakh
A	Cash Flow From Operating Activities		
	Net Profit before tax and Extraordinary Items	-2.23	0.81
	Adjustment for :		
	Depreciation	0.16	0.16
	Operating Profit before working Capital Changes	-2.07	0.97
	Adjustment for Capital Changes:		
	Increase/Decrease in Current Liabilities & Provisions	-2.06	14.48
	Increase/Decrease in Trade Payables	-0.06	0.12
	Increase/Decrease in Fixed Assets	-	-
	Increase/Decrease in Cash Loans and advances	0.19	29.28
	Increase/Decrease in Trade Receivables	-44.58	6.95
	Cash Generated From Operations	-48.58	51.80
	Income Tax / Deferred Tax Paid	1.42	0.25
	Extraordinary items	0.00	0.00
	Net cash from Operating Activities	-50.00	51.55
	B	Net Cash From Investing Activities	-
C	Net Cash Flow From Financing Activities	-	-
Net Increase (Decrease) in cash & cash equivalents (A+B+C)	-50.00	51.55	
Opening Balance of Cash & Cash Equivalents	51.63	0.08	
Closing Balance of Cash & Cash Equivalents	1.63	51.63	

As per our Report of even date.

For and on behalf of Board of Director:
Rubra Medicaments Limited



Abha Kapoor
Director (Finance) & CFO
DIN: 02799429

Mumbai
Date: May 25, 2022



MEDICAMENTS LTD.

Reg. Office: 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

Email ID: rubraltd@gmail.com | **Website:** www.rubramed.com

CIN: L74110MH1991PLC326598 | **Tel:** +91 9167469649

May 25, 2022

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code : 531099

Sub : Declaration on the Independent Auditors' Report with unmodified opinion pursuant to Regulation 33 (3)(d) of the SEBI (LODR) Regulations, 2015

DECLARATION

I, Abha Kapoor, Director (Finance) & CFO of the Company hereby declare that, the Statutory Auditors of the Company have issued an Independent Audit Report with unmodified/unqualified opinion on Annual Audited Standalone Financial Results of the Company for the year ended March 31, 2022.

For **Rubra Medicaments Limited**

A handwritten signature in blue ink, appearing to read "Abha Kapoor", with a horizontal line underneath.

Abha Kapoor
Director (Finance) & CFO
DIN - 02799429